---
layout: default
title: Abacavir
parent: 僅模型預測 (L5)
nav_order: 36
evidence_level: L5
indication_count: 3
---

# Abacavir
{: .fs-9 }

證據等級: **L5** | 預測適應症: **3** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ABACAVIR (DB01048): Drug Repurposing Evaluation — Insufficient Data to Complete Assessment

## One-Sentence Summary

ABACAVIR is an antiretroviral agent (DrugBank ID: DB01048) that was queried for drug repurposing potential via the TxGNN pipeline.
However, this Evidence Pack contains **no predicted indications**, **no original indication records**, and **no safety data** — the evaluation cannot proceed beyond the preliminary stage.
The data collection phase must be completed before any repurposing direction can be assessed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no regulatory records found) |
| Predicted New Indication | Not available (no TxGNN predictions in this pack) |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — pipeline incomplete |
| Market Status (Taiwan) | Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Is Available

This Evidence Pack (version v4, candidate `TW-DB01048-multi`) was generated with only one data source successfully retrieved: **DrugBank** (query ID 3, returned 1 record). Two critical data gaps were flagged at the time of pack creation:

| Gap ID | Item | Severity | Impact |
|--------|------|----------|--------|
| DG001 | TFDA package insert warnings / contraindications | Blocking | Cannot enter Safety S1 screening |
| DG002 | Mechanism of action (MOA) | High | Cannot perform mechanistic relevance analysis |

Because the TFDA regulatory query (query ID 1) returned zero records and the `predicted_indications` array is empty, **no repurposing candidate has been generated for ABACAVIR in this pipeline run**. Without a predicted indication, sections covering clinical trial evidence, literature evidence, mechanism rationale, and cytotoxicity assessment cannot be produced.

---

## Market Information (Taiwan)

No Taiwan TFDA license records were found for ABACAVIR. The drug is currently **not marketed** in Taiwan under any registered product.

---

## Safety Considerations

Please refer to the package insert for safety information. No safety data (warnings, contraindications, or drug interactions) was retrievable in this pipeline run.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is structurally incomplete — the TxGNN prediction pipeline did not produce any candidate indications for ABACAVIR, and all safety screening inputs are missing. No forward evaluation is possible in this state.

**To proceed, the following is needed:**

1. **Retrieve TFDA package insert** — Download and parse the official TFDA PDF for ABACAVIR to populate warnings, contraindications, and approved indications. This resolves the Blocking gap (DG001) and unblocks S1 safety screening.
2. **Retrieve MOA from DrugBank API** — Query `https://api.drugbank.com/v1/drugs/DB01048` for the mechanism of action field to resolve DG002 and enable mechanistic analysis.
3. **Re-run the TxGNN prediction pipeline** — Once original indications and MOA are populated, re-execute the KG and DL prediction steps to generate `predicted_indications`.
4. **Re-run evidence collectors** — After predictions are available, trigger ClinicalTrials.gov, PubMed, and ICTRP collectors to populate clinical trial and literature evidence for the top predicted indication.
5. **Regenerate Evidence Pack v5** — With all inputs resolved, a complete evaluation report can be produced.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

